Project Grant R43AG071040

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This federal Project Grant award, with ID RF1AG084635, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The $1,980,378 grant aims to develop small molecule inhibitors that can target the CAPON protein, which has been identified as a novel therapeutic target for Alzheimer's disease. The award supports research to screen a chemical library, identify CAPON-binding small molecules that can inhibit CAPON's interactions with tau protein and nitric...

Federal Grant Award Summary Alphamemory, LLC received a Phase I Small Business Technology Transfer (STTR) award of $504,248 from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop novel therapeutics for Alzheimer's disease. The award, issued on September 20, 2025, with a completion date of September 19, 2027, supports drug discovery efforts targeting the transmembrane domain of amyloid precursor protein (APP) as an alternative to gamma-secretase inhibitors,...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...

This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....

Federal Grant Award Summary Glial Therapeutics, LLC received a $254,896 Phase I Small Business Technology Transfer (STTR) grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 20, 2025, with completion anticipated by May 31, 2027. The company is conducting preclinical and translational research to develop ADWA11, a humanized monoclonal antibody that pharmacologically inhibits the αVβ8 integrin (ITGB8) to restore astrocyte-microglia...

Project Grant Summary Ceiba Bio Inc. received a $506,198 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) on September 15, 2025, with a completion date of August 31, 2026. The award supports the development of platelet-derived exercise mimetics as a novel therapeutic treatment for Alzheimer's disease (AD) and Alzheimer's disease-related dementias. The project addresses a significant clinical gap, as over one-quarter of elderly patients...

This $1,969,620 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research at Yale University focused on understanding how the Bcl-2 family protein Bok regulates neuronal cell death in Alzheimer's disease and other tauopathies. The key objectives are to examine how Bok controls the transfer of calcium from the endoplasmic reticulum to...

The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...